Use of BNP and CRP as biomarkers in assessing cardiovascular disease

Diagnosis versus risk

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. However, they differ in function, sensitivity and specificity. BNP is released from the myocardium in response to myocardial stretch, a clear cause and effect relationship; therefore, it is useful in the diagnosis of heart failure when patients present with dyspnea of unknown origin and to assess treatment in high risk patients with diagnosed heart failure. Sex and age based reference ranges and partition values are established from clinical trials and from populations screened for the absence of cardiovascular disease. Highly sensitive and reproducible methods are also available to measure CRP. However, although CRP is associated with adverse cardiovascular events, unlike BNP, multiple stimuli increase production of CRP. Therefore, elevation in CRP is not specific to cardiovascular disease. Partition values for CRP, and cardiovascular risk based on epidemiological studies predict risk for populations but may not always be useful when used alone to predict individual risk or to direct therapy. Given the non-specific stimuli which affect circulating concentrations of CRP, using CRP to monitor treatment to reduce cardiovascular risk may provide little benefit without understanding or targeting the underlying causes for its elevation.

Original languageEnglish (US)
Pages (from-to)15-25
Number of pages11
JournalCurrent Vascular Pharmacology
Volume5
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Brain Natriuretic Peptide
C-Reactive Protein
Cardiovascular Diseases
Biomarkers
Heart Failure
Sensitivity and Specificity
polypeptide C
Therapeutics
Protein C
Dyspnea
Population
Epidemiologic Studies
Myocardium
Reference Values
Medicine
Clinical Trials

Keywords

  • B-type natriuretic peptide
  • BNP
  • C-reactive protein
  • Coronary artery disease
  • CRP
  • Estrogen
  • Heart failure
  • Hormone replacement therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Use of BNP and CRP as biomarkers in assessing cardiovascular disease : Diagnosis versus risk. / Miller, Virginia M; Redfield, Margaret May; McConnell, Joseph P.

In: Current Vascular Pharmacology, Vol. 5, No. 1, 01.2007, p. 15-25.

Research output: Contribution to journalArticle

@article{8f070425bf3f4ad9a6915c2c9529c6f7,
title = "Use of BNP and CRP as biomarkers in assessing cardiovascular disease: Diagnosis versus risk",
abstract = "Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. However, they differ in function, sensitivity and specificity. BNP is released from the myocardium in response to myocardial stretch, a clear cause and effect relationship; therefore, it is useful in the diagnosis of heart failure when patients present with dyspnea of unknown origin and to assess treatment in high risk patients with diagnosed heart failure. Sex and age based reference ranges and partition values are established from clinical trials and from populations screened for the absence of cardiovascular disease. Highly sensitive and reproducible methods are also available to measure CRP. However, although CRP is associated with adverse cardiovascular events, unlike BNP, multiple stimuli increase production of CRP. Therefore, elevation in CRP is not specific to cardiovascular disease. Partition values for CRP, and cardiovascular risk based on epidemiological studies predict risk for populations but may not always be useful when used alone to predict individual risk or to direct therapy. Given the non-specific stimuli which affect circulating concentrations of CRP, using CRP to monitor treatment to reduce cardiovascular risk may provide little benefit without understanding or targeting the underlying causes for its elevation.",
keywords = "B-type natriuretic peptide, BNP, C-reactive protein, Coronary artery disease, CRP, Estrogen, Heart failure, Hormone replacement therapy",
author = "Miller, {Virginia M} and Redfield, {Margaret May} and McConnell, {Joseph P.}",
year = "2007",
month = "1",
doi = "10.2174/157016107779317251",
language = "English (US)",
volume = "5",
pages = "15--25",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Use of BNP and CRP as biomarkers in assessing cardiovascular disease

T2 - Diagnosis versus risk

AU - Miller, Virginia M

AU - Redfield, Margaret May

AU - McConnell, Joseph P.

PY - 2007/1

Y1 - 2007/1

N2 - Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. However, they differ in function, sensitivity and specificity. BNP is released from the myocardium in response to myocardial stretch, a clear cause and effect relationship; therefore, it is useful in the diagnosis of heart failure when patients present with dyspnea of unknown origin and to assess treatment in high risk patients with diagnosed heart failure. Sex and age based reference ranges and partition values are established from clinical trials and from populations screened for the absence of cardiovascular disease. Highly sensitive and reproducible methods are also available to measure CRP. However, although CRP is associated with adverse cardiovascular events, unlike BNP, multiple stimuli increase production of CRP. Therefore, elevation in CRP is not specific to cardiovascular disease. Partition values for CRP, and cardiovascular risk based on epidemiological studies predict risk for populations but may not always be useful when used alone to predict individual risk or to direct therapy. Given the non-specific stimuli which affect circulating concentrations of CRP, using CRP to monitor treatment to reduce cardiovascular risk may provide little benefit without understanding or targeting the underlying causes for its elevation.

AB - Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. However, they differ in function, sensitivity and specificity. BNP is released from the myocardium in response to myocardial stretch, a clear cause and effect relationship; therefore, it is useful in the diagnosis of heart failure when patients present with dyspnea of unknown origin and to assess treatment in high risk patients with diagnosed heart failure. Sex and age based reference ranges and partition values are established from clinical trials and from populations screened for the absence of cardiovascular disease. Highly sensitive and reproducible methods are also available to measure CRP. However, although CRP is associated with adverse cardiovascular events, unlike BNP, multiple stimuli increase production of CRP. Therefore, elevation in CRP is not specific to cardiovascular disease. Partition values for CRP, and cardiovascular risk based on epidemiological studies predict risk for populations but may not always be useful when used alone to predict individual risk or to direct therapy. Given the non-specific stimuli which affect circulating concentrations of CRP, using CRP to monitor treatment to reduce cardiovascular risk may provide little benefit without understanding or targeting the underlying causes for its elevation.

KW - B-type natriuretic peptide

KW - BNP

KW - C-reactive protein

KW - Coronary artery disease

KW - CRP

KW - Estrogen

KW - Heart failure

KW - Hormone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=34247142940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247142940&partnerID=8YFLogxK

U2 - 10.2174/157016107779317251

DO - 10.2174/157016107779317251

M3 - Article

VL - 5

SP - 15

EP - 25

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 1

ER -